| Trial ID # | NCT02726997 |
| Phase | I/II |
| Drug Class | Immunotherapy: Checkpoint Inhibitors/PD-L1 |
| Drug Name | Durvalumab |
| Alternate Drug Names | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi |
| Drugs in Trial | Carboplatin, Durvalumab, Paclitaxel |
| Eligible Participant | Newly diagnosed stage III/IV ovarian cancer (neo-adjuvant) |
| Patients Enrolled | 18 (50% stage III, 50% stage IV) |
| Therapy Setting | First-line |
| Study Design | Open-Label, Non-randomized |
| Endpoints | PFS, evaluated per RECIST |
| Efficacy | 83% obtained optimal cytoreduction at surgery |
| Clinically Significant Adverse Events | Serious AE: |
| Conclusion | Durvalumab with chemotherapy in upfront ovarian cancer and continued as maintenance is safe and shows reasonable efficacy |
| Reference | Westin SN et al. Pharmacodynamic changes by durvalumab in combination with chemotherapy in women with untreated, advanced stage ovarian cancer. AACR (2020) abstract CT188 |